23andMe Holding Co.

ME

US90138Q1085

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
0.3964 ^USD	-3.79%		-1.91%	-56.61%

Jun. 10	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Jun. 10	Sector Update: Health Care Stocks Retreat Monday Afternoon	MT

23andMe Holding Co. Reports Unaudited Consolidated Goodwill Impairment for the Fourth Quarter Ended March 31, 2024

May 23, 2024 at 04:05 pm EDT

23andMe Holding Co. reported unaudited consolidated goodwill impairment for the fourth quarter ended March 31, 2024. For the quarter, the company reported goodwill impairment of $152,944,000.

Latest news about 23andMe Holding Co.

Sector Update: Health Care Stocks Advance Late Afternoon	Jun. 10	MT
Sector Update: Health Care Stocks Retreat Monday Afternoon	Jun. 10	MT
23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October Data Breach	Jun. 10	MT
23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October 2023 Data Breach	Jun. 10	MT
Canada, UK launched joint probe into 23andMe data breach, says Canada	Jun. 10	RE
23andMe Faces Joint Probe From UK Information Commissioner's Office, Canada's Privacy Commissioner Office Over 2023 Data Breach	Jun. 10	MT
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, Targeting CD200R1, at the 2024 ASCO Annual Meeting	Jun. 03	CI
Earnings Flash (ME) 23ANDME Reports Q4 Revenue $64M, vs. Street Est of $61.5M	May. 23	MT
23andMe Q4 Loss Widens, Revenue Decreases	May. 23	MT
Transcript : 23andMe Holding Co., Q4 2024 Earnings Call, May 23, 2024	May. 23
23andMe Holding Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 23	CI
23andMe Holding Co. Reports Unaudited Consolidated Goodwill Impairment for the Fourth Quarter Ended March 31, 2024	May. 23	CI
Alibaba Cuts ADS Holdings by 60% in Q1	May. 15	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	May. 14	MT
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	May. 14	MT
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication	May. 14	MT
23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	CI
Petros, Lemonaid Health Collaborate to Expand Stendra Availability	Apr. 23	MT
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 18	DJ
US Equity Markets Close Mixed Thursday	Apr. 18	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 18	MT
Sector Update: Health Care Stocks Ease in Afternoon Trading	Apr. 18	MT
Sector Update: Health Care	Apr. 18	MT
Top Midday Stories: Taiwan Semiconductor Manufacturing, Blackstone, Elevance Health, D.R. Horton, Infosys and Marsh & McLennan Report Earnings; Tesla's Musk Says Laid-Off Employees Received "Incorrectly Low" Severance; 23andME CEO Mulls Taking Company Private; Northrop Grumman Working with SpaceX on Spy Satellite	Apr. 18	MT
23andMe CEO Mulls Plan to Take Company Private	Apr. 18	MT

23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customersâ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patientsâ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Sector

Healthcare Facilities & Services

Calendar

2024-08-06 - Q1 2025 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

INTERVIEW - Anne Wojcicki, CEO of 23andMe: partnership with Amazon and cancer treatment results

July 13, 2023 at 02:26 pm EDT

More Strategies

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3964 USD

Average target price

1.315 USD

Spread / Average Target

+231.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
23ANDME HOLDING CO.	-56.61%	194M
SONIC HEALTHCARE LIMITED	-19.54%	8.05B
RADNET, INC.	+68.16%	4.32B
DR. LAL PATHLABS LIMITED	+6.69%	2.74B
SYNLAB AG	-2.80%	2.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-50.95%	1.97B
NEOGENOMICS, INC.	-18.54%	1.68B
FLEURY S.A.	-21.29%	1.45B
METROPOLIS HEALTHCARE LIMITED	+16.69%	1.2B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-44.86%	1.12B

Medical & Diagnostic Laboratories